Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

The clinical development of new mitotic inhibitors that stabilize the microtubule ANTI-CANCER DRUGS Mani, S., Macapinlac, M., Goel, S., Verdier-Pinard, D., Fojo, T., Rothenberg, M., Colevas, D. 2004; 15 (6): 553-558

Abstract

Microtubule-stabilizing agents are increasingly studied for cancer treatment based largely on the prior success of paclitaxel and docetaxel. In this review, we focus on the clinical development of epothilones and discodermolide, and we discuss salient preclinical and clinical highlights of these two novel natural products. These agents are distinguished by their biochemical features making them poor P-glycoprotein substrates and capable of inducing cytotoxicity in cell lines or in vivo tumor models harboring mutations in tubulin. There is now considerable data regarding the efficacy of the epothilones in human beings and discodermolide holds such promise, as well.

View details for DOI 10.1097/01.cad.0000131681.21637.b2

View details for Web of Science ID 000222792600002

View details for PubMedID 15205596